Skip to main content

ERRATUM article

Front. Oncol., 20 September 2023
Sec. Hematologic Malignancies
Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1290218

Erratum: Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

This article is an erratum on:

  1. Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

    1. Read original article
Frontiers Production Office* Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study

by Lückemeier P, Radujkovic A, Holtick U, Kurch L, Monecke A, Platzbecker U, Herling M and Kayser S (2023) 13:1208028. doi: 10.3389/fonc.2023.1208028

Due to a production error, there was a mistake in the footnote for Table 1 as published. The abbreviations were written as ‘aSince/at diagnosis of PTLD, respectively. bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

7 + 3, cytarabine and daunorubicin; (s)AML, (secondary) acute myeloid leukemia; Assoc, associated; sAA, severe aplastic anemia; AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CAD, cyclophosphamide, doxorubicin, and dexamethasone; cALL, common acute lymphoblastic leukemia; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; cHL, classic Hodgkin lymphoma; CKD, chronic kidney disease; CNL, Chronic neutrophilic leukemia; DLBCL, diffuse large B-cell lymphoma; DLI, Donor lymphocyte infusion; GMALL07/2003, study protocol containing daunorubicin and doxorubicin; GMALL-B-NHL 2002, protocol containing R, Dexa, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; HCC, Hepatocellular carcinoma; IDA-FLAG, idarubicin, fludarabine, cytarabine, G-CSF; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; Monom, monomorphic; MTX, Methotrexate; PBL, lasmablastic lymphoma; PCL, plasma cell leukemia; PD, Progressive disease; Pola, Polatuzumab-Vedotin; PSC, Primary sclerosing cholangitis; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; T-LBL, Tlymphoblastic lymphoma; T1D, Type 1 diabetes; TAD, thalidomide, doxorubicin, Dexa; T-ALL, T-acute lymphoblastic leukemia; VST, Virus-specific T cells. Values in bold means the summarized values.’

The correct footnote appears below. The publisher apologizes for this mistake.

‘ aSince/at diagnosis of PTLD, respectively. bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

Abbreviations: 7 + 3=cytarabine and daunorubicin. (s)AML=(secondary) acute myeloid leukemia. assoc.=associated. sAA=severe aplastic anemia. CAD=cyclophosphamide, doxorubicin, and dexamethasone. cALL=common acute lymphoblastic leukemia. cHL=classic Hodgkin lymphoma. CKD=chronic kidney disease. CNL=Chronic neutrophilic leukemia. DLBCL=diffuse large B-cell lymphoma. GMALL07/2003=study protocol containing daunorubicin and doxorubicin. HCC=Hepatocellular carcinoma. IDA-FLAG=idarubicin, fludarabine, cytarabine, G-CSF. Mito-FLAG=mitoxantrone, fludarabine, cytarabine, G-CSF. monom.=monomorphic. PBL=Plasmablastic lymphoma. PCL=plasma cell leukemia. PD=Progressive disease. Pola=Polatuzumab-Vedotin. PSC=Primary sclerosing cholangitis. T-LBL=T-lymphoblastic lymphoma. T1D=Type 1 diabetes. TAD=thalidomide, doxorubicin, Dexa. T-ALL=T-acute lymphoblastic leukemia.’

The original version of this article has been updated.

Additionally, due to a production error, there was a mistake in the footnote for Table 2 as published. The abbreviations were written as ‘ aSince/at diagnosis of PTLD, respectively. bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CAD, cyclophosphamide, doxorubicin, and dexamethasone; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; DLBCL, diffuse large B-cell lymphoma; DLI, Donor lymphocyte infusion; GMALL07/2003, study protocol containing daunorubicin and doxorubicin; GMALL-B-NHL 2002, protocol containing R, Dexa, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; HCC, Hepatocellular carcinoma; IDA-FLAG, idarubicin, fludarabine, cytarabine, G-CSF; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; monom;, monomorphic; MTX, Methotrexate; PD, Progressive disease; Pola, Polatuzumab-Vedotin; PSC, Primary sclerosing cholangitis; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; thalidomide, doxorubicin, Dexa; VST, Virusspecific T cells. Values in bold means the summarized values.’

The correct footnote appears below. The publisher apologizes for this mistake.

‘aSince/at diagnosis of PTLD, respectively. bWhere applicable (i.e., CD20+, EBV-associated, IS still ongoing).

AVD, adriamycin, vinblastine, dacarbazine; Benda, Bendamustine; BV, brentuximab-vedotin; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; DLI, Donor lymphocyte infusion; GMALL-B-NHL 2002, protocol containing R, Dexa, vincristine, MTX, ifosfamide, cytarabine, etoposide, cyclophosphamide, doxorubicin; IS, immunosuppression; Mito-FLAG, mitoxantrone, fludarabine, cytarabine, G-CSF; monom, monomorphic; MTX, Methotrexate; PD, Progressive disease; Pola, Polatuzumab-Vedotin; R, Rituximab; RIS, Reduction of immunosuppression; RTx, Radiotherapy; VST, Virus-specific T cells.’

Due to a production error, there was a mistake in Table 1 as published. ‘IDA-FLAG’ was incorrectly written as ‘DA-FLAG’, ‘Alcoholic cirrhosis’ was incorrectly written as ‘alcoholic cinhosis’, and ‘‘Multiple Myeloma’ was incorrectly written as ‘Myelom’. The corrected Table 1 appears below. The publisher apologizes for this mistake.

TABLE 1
www.frontiersin.org

Table 1

Keywords: PTLD, Epstein - Barr virus, allogeneic hematopoietic stem cell transplantation, solid organ transplantation, outcome

Citation: Frontiers Production Office (2023) Erratum: Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study. Front. Oncol. 13:1290218. doi: 10.3389/fonc.2023.1290218

Received: 07 September 2023; Accepted: 07 September 2023;
Published: 20 September 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.